Niclosamide is a drug that has been identified to inhibit the Wnt/β-catenin and STAT3 cell signaling pathways, which are activated when cancer cells develop resistance to anticancer drugs, ...

Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue of drug resistance.

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metabolic anticancer drug aims to block signaling ...

ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate ...

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metabolic anticancer drug aims to block signaling ...

Niclosamide, however, has not been developed as an anticancer drug for over 60 years due to its low bioavailability and short half life. With its patented drug delivery system technology, ...

Niclosamide is found to be an antitumor agent that blocks metabolism, and Niclosamide-based anticancer drugs can solve the resistance and metastasis problems simultaneously. Due to its anticancer ...

Niclosamide was approved by the U.S. Food and Drug Administration (FDA) in 1982 for the treatment of intestinal tapeworm infections and has been safely used on millions of patients.

Niclosamide is toxic at antiviral concentrations after long-term exposure. A.) Workflow for high content anti-SARS-CoV-2 bioassay screening to determine infection inhibition and cytotoxicity.